Université Laval and Glycovax Pharma Enter into an Exclusive Global LicenseAgreement for the Development of Innovative Galectin-3 Inhibitors
Université Laval and Glycovax Pharma announce an exclusive global license agreement granting…
Our March 2026 newsletters are now available…
We are pleased to present the brand new February…
The BIOQuébec team is pleased to invite you to discover the …
A rich legacy for your association Dear members of the ecosystem, The past year has been one of action and…
As we approach the end of 2025, I would like to look back on the last few months, which have…
We are delighted to present the November 2025 edition of our newsletter. This new issue highlights …
We are pleased to bring you the October 2025 edition of our newsletter. In this new issue, we invite you…
August was another busy month for BIOQuébec, with 50 events, meetings, and…
As the first half of the year draws to a close, the summer months have been busy. BIOQuébec’s pace of…
Université Laval and Glycovax Pharma announce an exclusive global license agreement granting…
We use cookies to improve your browsing experience and analyze our traffic. By clicking "Accept", you consent to our use of cookies.
Privacy Policy